Theratechnologies Inc THTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if THTX is a good fit for your portfolio.
News
-
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
-
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
-
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
-
Theratechnologies Reports on its Annual Meeting of Shareholders
-
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
-
Theratechnologies Shares Sink Premarket After FDA Refusal to File Letter
-
Theratechnologies Shares Sink at Open After FDA Rejects Newer Tesamorelin Formulation
-
Theratechnologies Shares Slide Premarket as FDA Turns Away Newer Egrifta
Trading Information
- Previous Close Price
- $1.45
- Day Range
- $1.41–1.51
- 52-Week Range
- $0.88–3.29
- Bid/Ask
- $1.45 / $1.58
- Market Cap
- $66.90 Mil
- Volume/Avg
- 53,575 / 36,678
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.69
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 103
- Website
- https://www.theratech.com
Comparables
Valuation
|
Metric
|
THTX
|
039200
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 16.94 | 2.79 |
Price/Sales | 0.69 | 326.97 | 40.25 |
Price/Cash Flow | — | — | — |
Price/Earnings
THTX
039200
NYKD
Financial Strength
|
Metric
|
THTX
|
039200
|
NYKD
|
|---|---|---|---|
Quick Ratio | 0.95 | 2.63 | 8.43 |
Current Ratio | 1.10 | 2.73 | 8.43 |
Interest Coverage | 0.30 | −113.49 | — |
Quick Ratio
THTX
039200
NYKD
Profitability
|
Metric
|
THTX
|
039200
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −8.91% | −21.13% | −18.26% |
Return on Equity (Normalized) | — | −26.95% | −23.64% |
Return on Invested Capital (Normalized) | −0.89% | −28.78% | −26.98% |
Return on Assets
THTX
039200
NYKD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Dmlzsqyzxt | Nvxn | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tgqnhysp | Gnlvxr | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fxqslgw | Sgqjmf | $118.7 Bil | |||
| Moderna Inc
MRNA
| Lkxqpmdwz | Djrw | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yplwwhmh | Nyddyl | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Vwnbftsl | Sznrr | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qqgdpjwj | Zsdg | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cpfvdccb | Pdwztv | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Gprqzlnm | Cfljk | $15.0 Bil | |||
| Incyte Corp
INCY
| Vydbzjpt | Rngbgcy | $13.5 Bil |